The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-02. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
In many organisms including Xenopus and Drosophila, the midblastula transition usually occurs after a particular number of cell divisions for a given species, and is defined by the ending of the synchronous cell division cycles of the early blastula development, and the lengthening of the cell cycles by the addition of the G1 and G2 phases. Prior to this transition, cleavage occurs with only the synthesis and mitosis phases of the cell cycle. The addition of the two growth phases into the cell cycle allows for the cells to increase in size, as up to this point the blastomeres undergo reductive divisions in which the overall size of the embryo does not increase, but more cells are created. This transition begins the growth in size of the organism. The mid-blastula transition is also characterized by a marked increase in transcription of new, non-maternal mRNA transcribed from the genome of the organism. Large amounts of the maternal mRNA are destroyed at this point, either by proteins such as SMAUG in Drosophila or by microRNA. These two processes shift the control of the embryo from the maternal mRNA to the nuclei.
Calcium is a chemical element; it has symbol Ca and atomic number 20. As an alkaline earth metal, calcium is a reactive metal that forms a dark oxide-nitride layer when exposed to air. Its physical and chemical properties are most similar to its heavier homologues strontium and barium. It is the fifth most abundant element in Earth's crust, and the third most abundant metal, after iron and aluminium. The most common calcium compound on Earth is calcium carbonate, found in limestone and the fossils of early sea life; gypsum, anhydrite, fluorite, and apatite are also sources of calcium. The name comes from the Latin word calx (meaning "lime"), which was obtained from heating limestone. Some calcium compounds were known to the ancients, though their chemistry was unknown until the seventeenth century. Pure calcium was isolated in 1808 via electrolysis of its oxide by Humphry Davy, who named the element. Calcium compounds are widely used in many industries: in foods and pharmaceuticals for calcium supplementation, in the paper industry as bleaches, as components in cement and electrical insulators, and in the manufacture of soaps. On the other hand, the metal in pure form has few applications due to its high reactivity; still, in small quantities it is often used as an alloying component in steelmaking, and sometimes, as a calcium–lead alloy, in making automotive batteries. Calcium is the most abundant metal and the fifth-most abundant element in the human body.
Hypoglycemia (11 - 12%) - while it was shown to have the same efficacy as glimepiride, one of the newer sulfonylureas, the European GUIDE study has shown that it has approximately 50% less hypoglycemic confirmed episodes in comparison with glimepiride. Uncommon adverse effects between 1 - 10%:
Edelman, Under Secretary of Defense for Policy, described the shelling of the Georgian villages in hearing of the United States Senate Committee on Armed Services and said that Russian peacekeepers neglected their obligation to curb artillery fire and that Georgian military began to quell artillery sites in South Ossetia on the night of 7 August. Edelman said that although Russian officials had claimed that Russia's goal was defense of Russian citizens and peacekeepers, "What became clear is there never seemed to be a limit to Russia's operational – nor strategic – aims." Edelman said that the Russian invasion was pre-planned. According to Edelman, although Putin had blamed the United States for arming Georgia, the United States had never intended for the Georgian forces to oppose Russia. Edelman further stated, "Russia was clearly adding to tension in order to provoke a Georgian response." Edelman said that the first modern Russian invasion of foreign country "sends a chilling message" about new Russian foreign policy. In September 2008, Dana Rohrabacher (a senior Republican member of the United States House of Representatives) argued at a United States House Committee on Foreign Affairs meeting that Georgia started the fighting on August 7, citing alleged unnamed intelligence reports. Telegraph noted the Russian media paid much attention to Rohrabacher's remarks. In September 2008, Senator Hillary Clinton proposed to create a U.S. commission to study the war.
Sources: en.wikipedia.org
Eukaryotic translation initiation factor 4E, also known as eIF4E, is a protein in humans encoded by the EIF4E gene. eIF4E plays a central role in translation initiation and is involved in regulating protein synthesis. Its mRNA cap-binding activity influences a range of biological processes and disease states, making it an important target for therapeutic development, particularly in disorders characterized by aberrant protein production.
== Research and publications == Kalra has emphasised the importance of person-centred care for over a decade through his reviews, research, and communications in various national and international journals. One of his earlier citations on this topic dates back to a paper he led in 2013, in which he described the role of a person-centred approach during insulin initiation and intensification—one of the most challenging aspects of diabetes management.79 Although a substantial body of his work has focused on diabetes,77,79 he has also applied the principles of person-centred care to other chronic metabolic disorders, including obesity, hypogonadism, and hypothyroidism.78 Kalra has written on menopause distress and late-onset male hypogonadism, simplifying their definitions and describing person-centric thresholds, targets, tools, and techniques for management.167,168 He is also the lead author of a paper titled Thyroid Tantrums in Teenagers, which highlights the variability in endocrine presentations during adolescence and addresses management, assessment, testing techniques, associated biomedical illness, and training. His work extends across all age groups; for instance, he has published geriatric goalposts on independence and interdependence, emphasising the importance of person-centric care in older adults. Key principles of person-centred care highlighted in Kalra's publications include effective communication with patients.65,102 Other core principles include ensuring that therapy is affordable and that the management plan is feasible for the patient.
=== Bottom-up methods === Bottom-up methods involve the assembly of atoms or molecules into nanostructured arrays. In these methods the raw material sources can be in the form of gases, liquids, or solids. The latter require some sort of disassembly prior to their incorporation onto a nanostructure. Bottom up methods generally fall into two categories: chaotic and controlled. Chaotic processes involve elevating the constituent atoms or molecules to a chaotic state and then suddenly changing the conditions so as to make that state unstable. Through the clever manipulation of any number of parameters, products form largely as a result of the insuring kinetics. The collapse from the chaotic state can be difficult or impossible to control and so ensemble statistics often govern the resulting size distribution and average size. Accordingly, nanoparticle formation is controlled through manipulation of the end state of the products. Examples of chaotic processes are laser ablation, exploding wire, arc, flame pyrolysis, combustion, and precipitation synthesis techniques. Controlled processes involve the controlled delivery of the constituent atoms or molecules to the site(s) of nanoparticle formation such that the nanoparticle can grow to a prescribed sizes in a controlled manner. Generally the state of the constituent atoms or molecules are never far from that needed for nanoparticle formation. Accordingly, nanoparticle formation is controlled through the control of the state of the reactants.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.